Short term outcomes of Pulmonary Embolism: A National Perspective
Clinical Cardiology,Volume 0, Issue ja, -Not available-.
A 64-year old female with a history of a pulmonary embolism on rivaroxaban, breast cancer (mastectomy in 2013), hypertension, and diabetes presented for fatigue for one month. She had intermittent hemoptysis for six months. She was brought to the emergency department complaining of fatigue. Blood pressure was elevated to 165/75 mmHg. On exam, she appeared lethargic with pale conjunctiva and leg edema. She did not have a skin rash. Laboratory studies were significant for creatinine of 15.3 mg/dL, blood urine nitrogen 140 mg/dL, potassium 6.5 mEq/L.
Journal of Clinical Sleep Medicine, Ahead of Print.
In this study, we set different probability thresholds to test the performance of U-Net for the clot detection and selected sensitivity, specificity, and area under the curve (AUC) as the metrics of performance evaluation. Furthermore, we investigated the relationship between the clot burden assessed by the Qanadli score, Mastora score, and other imaging parameters on CTPA and the clot burden calculated by the DL-CNN model.ResultsThere was no statistically significant difference in AUCs with the different probability thresholds. When the probability threshold for segmentation was 0.1, the sensitivity and specificity of U-N...
Conclusions: This technique for sternal replacement in our experience can be considered safe with long term results, providing optimal chest wall stability. The allograft resulted well-tolerated permitting an optimal graft integration in the host. PMID: 32055417 [PubMed]
CONCLUSIONS: Prompt diagnosis and appropriate pre-operative imaging are mandatory in order to offer the best treatment modality. Open resection with revascularization seems to be the treatment of choice for arterial aneurysms, although endovascular procedures became more popular. Venous aneurysms require excision without revascularization. PMID: 32052949 [PubMed - as supplied by publisher]
ConclusionsHigh-sensitivity D-dimer remains the most clinically established VTE biomarker. Current research endeavors are under way to identify more precise biomarkers of VTE and PTS.
Publication date: March 2020Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders, Volume 8, Issue 2Author(s): Daniel Myers, Patrick Lester, Reheman Adili, Angela Hawley, Laura Durham, Veronica Dunivant, Garrett Reynolds, Kiley Crego, Zoe Zimmerman, Suman Sood, Robert Sigler, William Fogler, John Magnani, Michael Holinstat, Thomas WakefieldAbstractObjectiveThere is an inter-relationship between thrombosis and inflammation. Previously, we have shown the importance of P-selectin in thrombogenesis and thrombus resolution in many preclinical animal models. The role of E-selectin has been explored in rodent models...
Publication date: Available online 14 February 2020Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): Chengwei Zhang, Qiao Li, Hang Yu, Fang Wang, Ziyi Lin, Weiwei Yin, Yijia Pan, Mengqi Wu, Weidong Xie, Xuehai Chen, Naxin LiuAbstractObjectiveLower extremity deep venous thrombosis (LEDVT) is common and can lead to pulmonary embolism (PE). Currently, the mechanism of how LEDVT causes PE is unclear. The aim of this study was to explore the relationship between the thrombus sites and PE in LEDVT patients.MethodsA retrospective study that included the medical data of 3101 patients aged>18 yea...
The objective of this study was to evaluate complications of Greenfield (Boston Scientific, Marlborough, Mass) stainless steel inferior vena cava (IVC) filters on follow-up computed tomography (CT) imaging and to elucidate associated risk factors.MethodsNinety-three patients with CT studies obtained for other reasons after Greenfield IVC filter placement (2007-2014) were retrospectively studied. Greenfield filters were placed permanently in those with venous thromboembolism and an expected lifelong contraindication to anticoagulation or life expectancy
ConclusionsVenaSeal system is a promising therapeutic option for anatomic success at 6 months, with fewer occurrences of adverse events (wound and groin infection, pulmonary embolism) in CVI patients compared with other interventions in this study. Additional economic analysis including cost-effectiveness analysis would provide interesting perspectives on real-world insights to patients, payers, and providers.